Telix

Telix Introduction

Khaled Attia

Telix Pharmaceuticals





About Telix

Telix

Purpose & Mission

Our Purpose

We help people with cancer and rare diseases live longer, better quality lives

Our Mission

To deliver on the promise of precision medicine through targeted radiation

Core pipeline: oncology & rare diseases

	TARGETING AGENT	ISOTOPE	Dx/ Tx	PHASE 1	PHASE 2	PHASE 3	COMMERCIAL	UPCOMING MILESTONES
Prostate PSMA[1]	Antibody	^{177}Lu	Tx	TLX591 (^{177}Lu rosopatamab tetraxetan)				ProstACT GLOBAL interim readout: Q1 2025
	Antibody	α (alpha)	Tx	TLX592 (alpha-RADmAb®)				Phase 1 CUPID trial results: H1 2024
	Small molecule	^{68}Ga	Dx	TLX591-CDx (^{68}Ga-PSMA-11, Illuccix®)				EU approval decision: H1 2024 Phase 3 China bridging study complete: H2 2024
Kidney CAIX[2]	Antibody	^{177}Lu	Tx	TLX250 (^{177}Lu-girentuximab)				Phase 2 trial data readouts: H2 2024
	Antibody	^{89}Zr	Dx	TLX250-CDx (^{89}Zr-girentuximab, Zircaix™*)				FDA approval decision: H2 2024
Brain LAT-1[3]	Small molecule	^{131}I	Tx	TLX101 (^{131}I-IPA)				Phase 1 IPAX-2 trial data readout: H1 2025
	Small molecule	^{18}F	Dx	TLX101-CDx (^{18}F-floretyrosine)				FDA approval decision: H2 2024
STS[4] PDGFRα[5]	Antibody	Undisclosed	Tx	TLX300 (-olaratumab)				Phase 1 trial commencement: H1 2024
	Antibody	^{89}Zr	Dx	TLX300-CDx (^{89}Zr-olaratumab)				
BMC[6] CD66[7]	Antibody	^{90}Y	Tx	TLX66 (^{90}Y-besilesomab)				Phase 2 trial commencement: H1 2024
	Antibody	^{99m}Tc	Dx	TLX66-CDx (^{99m}Tc-besilesomab, Scintimun®[8])				

Telix

*Note: Nominated brand name subject to final regulatory approval.

1. Prostate-specific membrane antigen.
2. Carbonic anhydrase IX.
3. L-type amino acid transporter 1.
4. Soft tissue sarcoma.
5. Platelet derived growth factor receptor alpha.
6. Bone marrow conditioning.
7. Cluster of differentiation 66.
8. Marketed under license by Curium Pharma.

Research pipeline: novel targets and technologies

ASSET	TARGET	ISOTOPE	DESCRIPTION	STATUS
Immuno-oncology				
TLX250 Combo	CAIX	^{177}Lu	TLX250 + Merck KGaA DNA Damage Response Inhibitor (DDRi) candidate in patients with CAIX-expressing solid tumors	Phase Ib study (STARSTRUCK) to commence 1H 2023
Targeted alpha therapy				
α-TLX250	CAIX	^{211}At	Exploring TLX250 as an alpha therapy, in non-muscle invasive bladder cancer (in partnership with ATONCO). First -in-human study in planning	Phase I proof of concept study (PERTINENCE) completed
TLX592	PSMA	^{225}Ac	Utilizes Telix proprietary engineered antibody TLX592 (^{64}Cu/^{225}Ac-RADmAb®) in prostate cancer, as an alpha therapy candidate	Phase I study (CUPID) in progress
Tumor microenvironment				
TLR300	PDGFRα[1]	Undisclosed	Exploring the development and commercialization of radiolabelled forms of olaratumab for the diagnosis and treatment of human cancers, in-licensed from Lilly	IND enabling studies planned for 2023
TLR400	La/SSB[2]	Undisclosed	Novel antibody targeting La/SSB protein in lung and ovarian cancer, in partnership with AusHealth	Phase I study in progress
Radio-guided surgery				
TLX591-Sx	PSMA	^{68}Ga/IRDye	Dual-labelled PSMA-targeting molecule that comprises both a radioactive isotope (^{68}Ga) and a fluorescent dye	Phase 0 (biodistribution) clinical studies in progress
Illuccix life cycle management				
TLX599-CDx	PSMA	^{99m}Tc	NOBLE Registry in partnership with Oncidium Foundation exploring use of ^{99m}Tc-iPSMA for imaging of prostate cancer where SPECT is the predominant modality	Actively recruiting at eight sites in global registry

1. Platelet derived growth factor receptor alpha.
2. Small RNA binding exonuclease protection factor La.

Note: TLR designates a research asset that has not yet achieved product candidate status.

Example of Alpha project

Preclinical development of 225Ac-TLX592

Telix

Phase 3 *Ex vivo* biodistribution & Ac-225 dosimetry in immunocompetent CD1 mice, including assessment of two mass dose levels

Group (N)*	TLX592 Mass Dose (µg)	Volume & Route of Injection	Radioactivity Dose (kBq)	Tissue Collection Time Points	Blood Collection Time Point**	Urine and Feces Collection Time Points
1 (N=15)	100	150 µL, bolus IV	18.5	4 h, 1 d, 2 d, 7 d, 21 d (n=3 per time point & group)	30 min (4 h cohort)	4 h and 1 d (1 d cohort)
2 (N=15)	250	150 µL, bolus IV	18.5			













- No significant difference seen in the soft tissues i.e., liver, lungs, spleen, muscle and heart
- Kidney retention in 250µg cohort in the early phase, however cleared over time.

About Telix Manufacturing Solutions (TMS)

Telix

Key pillars of Telix Manufacturing Solution (TMS)

Production activities (Telix pipeline & Magistral preparation services for Radiopharmacy)



Radionuclides Production

R&D

Quality Control

Logistics & Warehousing

Telix

Facility Overview



Building of ~2500 m² including:

- 9 GMP Production suites (Grade C) ; 5 initially equipped
- QC labs (radiochemical & microbiology labs)
- R&D labs
- Purification labs
- 2 Cyclotron vaults
- Warehouse & Logistic space
- Office space

Telix

Potential Areas of Telix Collaboration with AlphaMet

WP1: Activity standards and nuclear data

- Participation of Telix Manufacturing Solutions (TMS) in inter-comparison exercise
- Stakeholder input as radiopharmaceutical manufacturer with future requirement for traceable activity measurements

WP2: In-vivo SPECT quantification of activities

- Stakeholder input as end-user (radiopharmaceutical developer undertaking clinical studies involving quantitative SPECT with alpha emitters)

WP3: Quantification of absorbed doses

- Stakeholder input as end-user (radiopharmaceutical developer wishing to perform and understand dosimetry with alpha emitters)

WP4: Morphological imaging for marrow dosimetry

- Stakeholder input as end user (radiopharmaceutical developer with particular interest in bone marrow dosimetry due to antibody-focused pipeline)

Telix

Thank You

Telix